Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Body weight between 40 and 90 kg, inclusive.~* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.~* A chest X-ray compatible with TB.~* Sputum positive~* Adequate volume of sputum~* Female participants of childbearing potential negative serum pregnancy and agree to use birth control~* Male participants must agree to use contraception throughout participation in the trial and for 12 weeks after last dose.~Exclusion Criteria:~* Poor general condition~* Rifampicin-resistant and/or Isoniazid-resistant~* MTB Treatment received within the 3 months prior~* Allergy to the IMP or related substances~* Evidence of extrathoracic TB~* A history of previous TB~* Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease~* History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic examination~* Any evidence of renal impairment~* For males, any evidence or history of abnormality in the reproductive system~* History and/or presence (or evidence) of neuropathy or epilepsy.~* Clinically relevant changes in the ECG~* A history of or current clinically relevant cardiovascular disorder~* Concomitant use of any drug known to prolong QTc interval~* Diabetics using insulin~* Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).~* Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP.~* Any disease or conditions in which any of the medicinal products listed in the section pertaining to prohibited medication is used.~* alcohol or drug abuse~* Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the half-life of the IMP is unknown within 1 month.~* Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks of cessation of treatment for males and within one week of cessation of treatment for females.~* Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes~* Any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.~* glucocorticoids within one year prior to dosing.~* HIV infection with helper/inducer T lymphocyte (CD4 cell) count of less than or equal to 300x10-6/L.~* Receiving antiretroviral therapy (ART).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- PA-824 50 mg/qd (Type: EXPERIMENTAL): None
- PA-824 100mg/qd (Type: EXPERIMENTAL): None
- PA-824 150mg/qd (Type: EXPERIMENTAL): None
- PA-824 200mg/qd (Type: EXPERIMENTAL): None
- Rifafour e-275mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete